Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for bleeding disorder: experimental drug HMB-002 enters human testing

NCT ID NCT06754852

First seen Jan 05, 2026 · Last updated May 23, 2026 · Updated 28 times

Summary

This study tests a new medicine, HMB-002, in 108 adults with von Willebrand disease (types 1 and 2). The goal is to check if the drug is safe, how the body processes it, and whether it helps control bleeding. Participants will receive either one or several doses of the drug, and researchers will monitor for side effects and measure drug levels in the blood.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fiona Stanley Hospital

    NOT_YET_RECRUITING

    Murdoch, Perth, WA 6150, Australia

  • Richmond Pharmacology

    RECRUITING

    London, SE1 1YR, United Kingdom

  • Royal Prince Alfred Hospital

    RECRUITING

    Camperdown, Sydney, NSW 2050, Australia

  • The Alfred Hospital

    RECRUITING

    Melbourne, Victoria, VIC 3004, Australia

Conditions

Explore the condition pages connected to this study.